| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 … SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ... The Lancet Oncology 21 (4), 519-530, 2020 | 701 | 2020 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 675 | 2017 |
| Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule J Baselga, X Carbonell, NJ Castañeda-Soto, M Clemens, M Green, ... Journal of Clinical Oncology 23 (10), 2162-2171, 2005 | 570 | 2005 |
| HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer … A Llombart-Cussac, J Cortés, L Paré, P Galván, B Bermejo, N Martínez, ... The lancet oncology 18 (4), 545-554, 2017 | 334 | 2017 |
| Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 … IE Krop, IA Mayer, V Ganju, M Dickler, S Johnston, S Morales, DA Yardley, ... The lancet oncology 17 (6), 811-821, 2016 | 310 | 2016 |
| Pathogenesis of Salmonella enteritidis infection in laying chickens. I. Studies on egg transmission, clinical signs, fecal shedding, and serologic responses HL Shivaprasad, JF Timoney, S Morales, B Lucio, RC Baker Avian diseases, 548-557, 1990 | 295 | 1990 |
| Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non–small-cell lung cancer: A Spanish Lung Cancer Group phase III … V Alberola, C Camps, M Provencio, D Isla, R Rosell, C Vadell, I Bover, ... Journal of clinical oncology 21 (17), 3207-3213, 2003 | 269 | 2003 |
| Capivasertib in hormone receptor–positive advanced breast cancer NC Turner, M Oliveira, SJ Howell, F Dalenc, J Cortes, HL Gomez Moreno, ... New England Journal of Medicine 388 (22), 2058-2070, 2023 | 218 | 2023 |
| Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial A Chan, B Moy, J Mansi, B Ejlertsen, FA Holmes, S Chia, H Iwata, ... Clinical breast cancer 21 (1), 80-91. e7, 2021 | 217 | 2021 |
| Aquatic degradation of triclosan and formation of toxic chlorophenols in presence of low concentrations of free chlorine P Canosa, S Morales, I Rodriguez, E Rubi, R Cela, M Gómez Analytical and bioanalytical chemistry 383, 1119-1126, 2005 | 213 | 2005 |
| Lysyl oxidase‐like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal‐like breast carcinomas G Moreno‐Bueno, F Salvador, A Martín, A Floristán, EP Cuevas, V Santos, ... EMBO molecular medicine 3 (9), 528-544, 2011 | 190 | 2011 |
| Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study M Martín, S Loibl, G von Minckwitz, S Morales, N Martinez, A Guerrero, ... Journal of Clinical Oncology 33 (9), 1045-1052, 2015 | 167 | 2015 |
| Microwave assisted extraction followed by gas chromatography with tandem mass spectrometry for the determination of triclosan and two related chlorophenols in sludge and sediments S Morales, P Canosa, I Rodríguez, E Rubí, R Cela Journal of Chromatography A 1082 (2), 128-135, 2005 | 161 | 2005 |
| Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer—the evaluating treatment with … L Gianni, M Mansutti, A Anton, L Calvo, G Bisagni, B Bermejo, ... JAMA oncology 4 (3), 302-308, 2018 | 151 | 2018 |
| Matrix vesicles produced by osteoblast-like cells in culture become significantly enriched in proteoglycan-degrading metalloproteinases after addition of β-glycerophosphate and … DD Dean, Z Schwartz, L Bonewald, OE Muniz, S Morales, R Gomez, ... Calcified tissue international 54, 399-408, 1994 | 133 | 1994 |
| HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade A Prat, T Pascual, C De Angelis, C Gutierrez, A Llombart-Cussac, T Wang, ... JNCI: Journal of the National Cancer Institute 112 (1), 46-54, 2020 | 129 | 2020 |
| Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial G von Minckwitz, M Colleoni, HC Kolberg, S Morales, P Santi, ... The Lancet Oncology 19 (7), 987-998, 2018 | 107 | 2018 |
| Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant … M Martin, C Zielinski, M Ruiz-Borrego, E Carrasco, N Turner, EM Ciruelos, ... Annals of oncology 32 (4), 488-499, 2021 | 104 | 2021 |
| Palbociclib and trastuzumab in HER2-positive advanced breast cancer: results from the phase II SOLTI-1303 PATRICIA trial E Ciruelos, P Villagrasa, T Pascual, M Oliveira, S Pernas, L Paré, ... Clinical Cancer Research 26 (22), 5820-5829, 2020 | 100 | 2020 |
| Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade F Brasó-Maristany, G Griguolo, T Pascual, L Paré, P Nuciforo, ... Nature communications 11 (1), 385, 2020 | 91 | 2020 |
